Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a GIST patient meeting in Seattle, he has provided our program with invaluable training and support.

“Dr. Wagner has gone above and beyond in advising our team on complex patient cases,” says Meg Mager, Senior Program Manager at The Max Foundation. “He’s helped us to better understand GIST so we can better support our patients. We are incredibly grateful for his support and are excited to have him join our Medical Advisory Board.”

Dr. Wagner is a medical oncologist at the Seattle Cancer Care Alliance, Assistant Member of the Fred Hutchinson Cancer Research Center, as well as an Assistant Professor at the University of Washington School of Medicine. After receiving a medical degree from Harvard University, he completed his residency at Mt. Sinai Hospital in New York, and a medical oncology fellowship at the University of Texas MD Anderson Cancer Center.

His research is dedicated to improving outcomes for patients with bone and soft tissue sarcomas which has led to early drug development and clinical trials. He’s received multiple awards for his work studying sarcomas, including the Conquer Cancer Foundation of ASCO Young Investigator Award and QuadW Foundation-AACR Fellowship for Clinical/Translational Research.

“As a sarcoma oncologist, I want to do what I can to get effective treatments for GIST available to all patients who would benefit,” said Dr. Wagner. “The Max Foundation does great work expanding access to critical cancer drugs and I am very excited to help those efforts.”

Increasing GIST Awareness

Our GIST program provides access to treatment and care to more than 2,000 patients in low- and middle-income countries worldwide. On July 13, we will be joining our patients and communities worldwide to commemorate GIST Awareness Day, a global initiative led by The Life Raft Group to bring awareness of, and education and advocacy for GIST to the general public.

In light of GIST Awareness Day, we’re including a Q&A with Dr. Wagner below to demystify GIST, learn more about his work, and help us spread further awareness to our patient and donor communities. Here are some of Dr. Wagner’s insights on GIST:

The Max Foundation: Can you tell us more about your background and what drew you to working with gastrointestinal stromal tumors, known as GIST, and the GIST patient advocate community?

Dr. Wagner: I was first exposed to GIST as a medical student working with Dr. George Demetri, and I continued doing research on sarcoma throughout my medical training. Getting a sarcoma diagnosis can be overwhelming. Access to high quality information is important for any cancer, but especially for rare cancers like GIST. The GIST patient advocacy community is incredibly important for educating patients about their disease and empowering patients to advocate for themselves and ensure they are getting appropriate treatment.

The Max Foundation: What would you say to a patient who was recently diagnosed? What do they need to know about this complicated disease?

Dr. Wagner: We have learned a great deal about the biology of GIST over the past ~20 years. As a result, there are therapies that have dramatically improved outcomes for GIST patients. As new drugs become available, knowing your KIT/PDGFRA mutation status is becoming more important. Consulting with a sarcoma specialist experienced in managing GIST early in your treatment course is highly recommended when possible because it is a relatively rare tumor that is treated very differently from most other types of cancer.

The Max Foundation: Are there any risk factors for GIST patients or treatment side-effects?

Dr. Wagner: There are some genetic syndromes that increase the risk of GIST, but the vast majority of cases arise in patients without any known major risk factors. Treatments for GIST can certainly have side effects, but the risks vary and not everyone experiences the same side effects. GIST patients should discuss potential side effects and management of those side effects with their treating physician.

The Max Foundation: We know that eating the right foods and a healthy diet are important for people living with GIST. What else can you tell us about this?

Dr. Wagner: This is true for anyone- with or without GIST. It is especially true for GIST patients because some patients with stomach or bowel resections can have nutritional deficiencies as a result of the surgery. It is important to be aware of what vitamins and nutrients might be affected by a surgery and to monitor for deficiencies.

The Max Foundation: Are there any unique challenges that GIST patients
in low and middle-income countries face?

Dr. Wagner: Because it is a rare cancer, GIST is generally best managed by sarcoma specialists who may not be readily available in low- and middle-income countries. The treatments also may be difficult to obtain and are expensive. In addition, mutation testing, which is becoming so critical to GIST treatment, is generally unavailable or cost prohibitive to patients in LMICs.

Learn more about GIST:

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

    Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

    Three women diagnosed with HER2- HR+ advanced breast cancer in Mozambique have begun treatment, with efforts underway to open access in eight additional countries  The Max Foundation leading initiative through its Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) with the goal of increasing access to treatment, care, and support at no cost to….

  • The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity

    The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity

    Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….

  • Join us November 6th for the International CML Foundation Forum at AORTIC

    Join us November 6th for the International CML Foundation Forum at AORTIC

    The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world. During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML. When: Wednesday,….